Key Takeaways
Exposure duration is redefining potency: Regulators and developers are prioritizing time-on-target, trough levels, and exposure profiles over peak concentration (Cmax) when evaluating drug performance.
PK/PD modeling now drives dosing and formulation decisions: Exposure–response analyses are central to selecting dose, dosing interval, and modified-release or long-acting formulations that balance efficacy and safety.
Long-acting therapies are reshaping clinical trial design: Maintenance endpoints, noninferiority frameworks, and switching studies are becoming standard as programs focus on preserving established outcomes through sustained exposure.
Delivery strategy directly impacts both efficacy and tolerability: By reshaping exposure curves rather than escalating dose, developers can reduce peak-related toxicity while maintaining therapeutic benefit.
Regulatory expectations increasingly reward exposure control: FDA, EMA, and ICH guidance emphasize comprehensive characterization of concentration–time profiles, reinforcing duration as a measurable and regulatable dimension of drug value.
From Peak Intensity to Exposure Control
Modern drug development is increasingly oriented around the shape and duration of drug exposure, rather than the pursuit of ever-higher peak concentrations (Cmax). This shift reflects a growing recognition that therapeutic performance is often governed by how long a drug remains within an effective exposure window, not simply how high concentrations rise at any single point in time. As a result, development decisions are progressively framed around managing exposure profiles across time, rather than maximizing dose intensity.
With this paradigm shift, the meaning of “potency” is quietly changing. Rather than being defined solely by milligram strength or peak systemic levels, potency is increasingly operationalized as time-on-target — the ability of a drug to sustain biologically relevant exposure long enough to drive efficacy while remaining within acceptable safety margins. This reframing does not reject traditional pharmacokinetic measures but places them within a broader exposure–response context in which duration, trough concentrations, and overall exposure patterns may be more informative than peak values alone.
This shift helps explain why extended-interval dosing, long-acting formulations, and maintenance-focused trial designs have gained prominence across therapeutic areas, and why regulatory and modeling frameworks increasingly emphasize exposure control as a core development objective rather than a secondary optimization step.
Regulatory Foundation: Exposure–Response and Time Course
Regulatory frameworks have long treated exposure–response relationships as foundational to drug evaluation, but their implications for development strategy have become more explicit over time. U.S. Food and Drug Administration (FDA) guidance states that exposure–response information sits at the center of regulatory determinations of both safety and effectiveness, because therapeutic benefit and adverse effects can only be interpreted meaningfully when related to a defined level of exposure.1 In this view, exposure is not merely a useful analytical construct but the pertinent lens through which clinical outcomes are understood and compared.
This regulatory perspective extends understanding beyond the amount of drug delivered to how exposure unfolds over time. FDA guidance emphasizes that both the magnitude and the time course of exposure and effect are relevant to core development decisions, including dose selection, dosing interval, monitoring strategies, and even the choice of dosage form, such as whether a controlled-release formulation is appropriate.1 This approach directly links pharmacokinetic behavior to formulation and regimen design, rather than treating these as downstream or purely operational considerations.
Within this context, commonly used pharmacokinetic summary metrics are acknowledged as useful but incomplete. Measures such as area under the curve (AUC), Cmax, and minimum concentration (Cmin) are described as convenient descriptors derived from concentration–time data, but FDA guidance explicitly notes that these metrics do not capture the full time course of exposure.1 Concentration–time profiles themselves can convey time-dependent information that cannot be inferred from AUC or Cmin alone, reinforcing the idea that understanding how exposure evolves is often as important as quantifying its overall magnitude.
These regulatory principles establish a clear foundation for thinking about drug performance in temporal terms and explain why exposure duration, profile shape, and maintenance of effective concentrations have become central considerations in modern development programs.
Which Exposure Metric Matters Depends on Context
While regulatory guidance establishes the importance of exposure and its time course, it does not prescribe a single exposure metric as universally decisive. Instead, the relevance of any given pharmacokinetic measure depends on the context in which it is applied. Reviews of regulatory and industry practice emphasize that exposure metric selection is shaped by study design, the underlying mechanism of action, and whether the clinical effects of interest are acute or long-term in nature.2 This context sensitivity underscores why different development programs may prioritize different aspects of the concentration–time profile.
Within this framework, specific exposure metrics tend to align with particular outcome types. Measures such as average concentration (Cavg) or trough concentration (Ctrough) are often informative for long-term or maintenance effects, where sustained exposure over time is central to therapeutic benefit. In contrast, peak concentration (Cmax) is more commonly explored in relation to acute adverse events, where transient high exposures may drive safety concerns. Steady-state area under the curve (AUCss) is frequently associated with cumulative or maintenance effects that depend on overall exposure rather than momentary intensity.2
Regulatory agencies have formalized this multidimensional view of exposure in their expectations for model-informed development. Guidance from the European Medicines Agency (EMA) indicates that model-based approaches may be used to support alternative dosing regimens, routes of administration, or formulations, as long as relevant pharmacokinetic metrics are adequately characterized and explicitly linked to both efficacy and safety outcomes. These metrics may include Cmin, AUC, and Cmax, and the associated exposure–response analyses may incorporate pharmacodynamic markers, such as receptor occupancy, when appropriate.3
Clinical pharmacology literature reinforces this regulatory stance by highlighting that toxicity does not map to a single exposure measure across all drugs or mechanisms. Depending on how adverse effects arise, toxicity may correlate most closely with trough concentrations, peak concentrations, or cumulative exposure, as reflected by AUC. This variability further supports the need to select exposure metrics deliberately, based on mechanism and clinical context, rather than defaulting to any one parameter as a proxy for overall risk or benefit.4
Mechanistic Basis: Time-on-Target and Residence Time
At a mechanistic level, the emphasis on exposure duration is grounded in the time-dependent nature of drug–target interactions. Target occupancy is not determined by concentration alone but by the interplay between drug levels and binding kinetics, including association, dissociation, and rebinding processes. From this perspective, sustained target engagement can be achieved not only by maintaining adequate systemic concentrations but also by slowing dissociation from the target or increasing the likelihood of rebinding once dissociation occurs.5
This helps explain why exposure duration can be a more meaningful driver of pharmacodynamic effect than peak concentration in many settings. When binding kinetics favor prolonged target engagement, the biological effect of a drug may persist even as circulating concentrations fluctuate, provided that exposure remains within a range that supports continued interaction with the target.
Experimental evidence supports this view. Studies examining drug–target residence time demonstrate that the duration of in vivo target binding is directly influenced by how long a drug remains associated with its target, independent of transient peaks in concentration. In such cases, residence time serves as a mechanistic bridge between pharmacokinetics and pharmacodynamics, linking sustained exposure to prolonged biological effect.6
Historical Anchor: Anti-Infective PK/PD as a Duration Paradigm
Anti-infective pharmacology provides one of the clearest historical examples of how exposure duration can govern therapeutic effect. In antibiotic development, pharmacokinetic–pharmacodynamic (PK/PD) relationships have long been framed around indices that explicitly incorporate time as a critical variable. Classical antibiotic PK/PD indices include the ratio of peak concentration to minimum inhibitory concentration (Cmax/MIC), the ratio of area under the concentration–time curve to MIC (AUC/MIC), and the proportion of the dosing interval during which drug concentrations remain above the MIC (time above MIC). These indices have been used extensively in antibiotic research and development since the 1980s, reflecting an early recognition that antimicrobial efficacy cannot be reduced to peak concentration alone.7
Among these indices, time above MIC offers a particularly clear illustration of duration-driven efficacy. Professional guidance notes that for certain antibiotics and bacterial isolates, once a target duration above the MIC has been achieved, further increases in free drug concentration beyond standard dosing may not yield additional bactericidal benefit for that isolate. In these cases, sustaining exposure over a sufficient portion of the dosing interval is more important than achieving higher transient peaks.8
Although this paradigm is specific to anti-infective therapy and cannot be directly generalized to all drug classes, it demonstrates that, in at least one well-characterized therapeutic area, maintaining exposure above a biologically relevant threshold over time has long been understood to outweigh the value of higher peak concentrations, foreshadowing many of the duration-focused strategies now appearing across other areas of drug development.
Delivery Alters Efficacy and Safety Simultaneously
As development strategies pivot toward exposure control, delivery decisions increasingly shape both efficacy and safety outcomes at the same time. Regulatory guidance frames exposure–response analysis as a joint evaluation of benefit and risk, emphasizing that therapeutic effects and adverse outcomes must be interpreted relative to the same exposure profile. From this perspective, exposure is the common currency through which efficacy and safety are assessed,rather than a parameter optimized independently for each domain.1 EMA guidance reinforces this view, noting that model-based approaches can support alternative dosing regimens, routes of administration, or formulations when pharmacokinetic metrics are characterized and explicitly linked to both efficacy and safety outcomes.3
This creates space for development strategies that manage risk by reshaping exposure rather than increasing dose. Clinical pharmacology literature highlights that safety signals may correlate most strongly with peak concentrations in some settings, while efficacy may be driven by other aspects of exposure, such as trough levels, average concentrations, or overall exposure over time. In such cases, modifying the exposure curve (e.g., by reducing peaks while maintaining adequate exposure across the dosing interval) can improve tolerability without compromising therapeutic effect.2,4 This logic positions formulation and dosing interval as tools for optimizing the therapeutic window, not merely for improving convenience.
A concrete cardiometabolic example illustrates this principle. In its clinical pharmacology review for semaglutide, the FDA notes that the once-weekly dosing regimen selected for phase III development was chosen in part because exposure simulations indicated a lower Cmax compared with daily dosing while maintaining appropriate overall exposure on a weekly basis. Here, dosing frequency and formulation strategy were used deliberately to shape the exposure profile in a way that balanced efficacy objectives with safety considerations.9
A similar exposure-driven rationale underpinned extended-interval dosing in oncology. The FDA approved pembrolizumab at 400 mg every six weeks as an alternative to the established 200 mg every three weeks regimen. This decision was not based on achieving higher peak concentrations but on PK data and exposure–response analyses demonstrating that the extended-interval regimen maintained exposure within the range associated with established efficacy and safety. Model-based exposure comparisons were used to support the equivalence of the two regimens, reinforcing the role of exposure shaping, rather than dose escalation, as the basis for regulatory acceptance.10,11
Where Long-Acting Formulations Change Trial Design
As exposure duration becomes a primary development variable, the central questions posed by clinical trials begin to shift. Rather than asking whether a new intervention delivers superior peak-driven efficacy, many long-acting programs are designed to test whether maintained exposure can preserve outcomes already established with more frequent dosing. Regulatory and modeling frameworks explicitly support this transition by positioning exposure–response analysis as a tool for evaluating dose, dosing interval, and formulation choices across development and at submission, which in turn legitimizes alternative frameworks focused on exposure maintenance rather than escalation.1,12
This shift has significant implications for trial design. Programs increasingly rely on noninferiority frameworks to assess whether extended dosing intervals maintain clinical benefit, emphasize maintenance endpoints rather than incremental efficacy gains, and use switching studies to evaluate transitions from established regimens to long-acting alternatives. These designs reflect the premise that the therapeutic effect is already known and that the remaining uncertainty lies in whether the exposure profile can be sustained over longer durations.1,12
Long-acting antipsychotics offer a clear illustration of this logic. In schizophrenia, a three-month paliperidone palmitate formulation (PP3M) was shown to be noninferior to the once-monthly formulation (PP1M) for relapse prevention in a phase III study using a predefined noninferiority margin.13 The corresponding ClinicalTrials.gov record explicitly frames PP3M as a maintenance therapy rather than a novel efficacy intervention, underscoring that the primary question was durability of disease control across a longer dosing interval.14 This approach was subsequently extended to a six-month formulation (PP6M), which demonstrated comparable, noninferior efficacy to PP3M for relapse prevention, reinforcing the focus on sustained exposure rather than increased intensity.15
A similar pattern appears in HIV treatment. In pooled analyses of the ATLAS and FLAIR phase III studies, monthly injections of long-acting cabotegravir plus rilpivirine were shown to be noninferior to daily oral therapy for maintaining virologic suppression in adults with HIV-1.16 The ATLAS trial was explicitly designed as a switching and maintenance study, assessing whether patients could transition from daily oral regimens to every-four-week injectable therapy without loss of viral control rather than seeking superior efficacy.17
In substance use disorder, long-acting formulations are similarly evaluated through maintenance and relapse prevention paradigms. The FDA-approved label for extended-release naltrexone specifies monthly intramuscular dosing for prevention of relapse to opioid dependence following detoxification.18 Earlier randomized, placebo-controlled trials tested sustained-release naltrexone using dosing intervals of approximately four weeks, directly examining whether maintained exposure could support abstinence over time.19 Comparative-effectiveness studies further reflect this maintenance focus: the X:BOT trial compares extended-release naltrexone with buprenorphine–naloxone for opioid relapse prevention, emphasizing real-world treatment effectiveness rather than peak pharmacodynamic effects.20
Across these therapeutic areas, a common trial design pattern emerges. Long-acting programs tend to prioritize maintenance endpoints, employ noninferiority logic to assess durability of effect, and use switching paradigms to evaluate transitions from established regimens to extended-interval dosing. This convergence suggests that, once exposure–response relationships are sufficiently characterized, development risk shifts away from demonstrating whether a drug works and toward demonstrating whether delivery strategies can reliably maintain the necessary exposure profile over time.12,13,15,16
Exposure Control as a Regulatory and Modeling Discipline
The increasing emphasis on exposure duration has been accompanied by a corresponding evolution in regulatory and modeling practice. Exposure–response analysis is now explicitly positioned as a decision-making tool that supports not only dose selection but also the choice of dosing interval and formulation strategy. Regulatory guidance makes clear that understanding how exposure relates to both efficacy and safety enables developers to justify alternative regimens and delivery approaches, provided those exposure–response relationships have been well characterized.1 Modeling and simulation frameworks reinforce this role by formalizing how exposure data can be integrated across development stages to inform these decisions in a systematic and reproducible way.12
This exposure-centric approach has particular implications for modified-release (MR) and long-acting formulations. Guidance and methodological literature note that extended-release products, especially those designed to produce relatively flat concentration–time profiles, may not be adequately characterized by traditional summary metrics such as AUC and Cmax alone. In these cases, time-related metrics and a more detailed examination of the concentration–time curve may be required to capture clinically relevant differences in exposure and to support meaningful comparisons between formulations.21
International guidance further reinforces the priority placed on exposure duration and completeness. The ICH M12 guideline specifies that, when studying substrates with long half-lives, study designs may need to ensure coverage of at least 90% of the plasma concentration–time curve. This requirement reflects an explicit recognition that partial or truncated exposure assessment can obscure clinically important effects and that capturing the full temporal profile of exposure is essential for robust interpretation.22
By elevating exposure shape and duration to first-class development variables, regulators and developers alike are increasingly treating formulation design, dosing interval selection, and trial structure as interdependent components of a coherent exposure strategy.
Conclusion: Exposure Control as the New Expression of Potency
The regulatory, mechanistic, and clinical patterns outlined above point to a seemingly minor but consequential reframing of potency in modern drug development. Potency is no longer understood solely as the ability to achieve high peak concentrations, but as a measurable, modelable, and regulatable property of exposure over time. Regulatory guidance has made clear that both efficacy and safety are functions of exposure magnitude and time course, and that concentration–time profiles often carry information that cannot be captured by summary metrics alone.
Within this framework, innovation increasingly resides in delivery and exposure engineering rather than dose escalation. Advances in modeling and simulation, coupled with clearer regulatory expectations, have enabled developers to justify alternative dosing intervals, modified-release formulations, and long-acting products by demonstrating how exposure profiles align with established exposure–response relationships. In this sense, formulation and regimen design have become active tools for optimizing therapeutic performance rather than downstream conveniences layered onto a fixed dose.2,21
This shift has also driven convergence across domains that were once treated separately. Trial design increasingly reflects exposure logic through maintenance endpoints, noninferiority frameworks, and switching studies. Regulatory strategy relies on exposure–response analyses to bridge formulations and dosing regimens. Formulation science, in turn, is guided by the need to shape exposure profiles that are defensible from both efficacy and safety perspectives. Collectively, these elements signal a maturation of the development ecosystem around a shared organizing principle: control of exposure, not maximization of intensity.
In that context, duration is no longer a secondary attribute or a convenience feature. It has become a central dimension of how therapeutic value is defined, evaluated, and regulated and is reshaping how drugs are designed, tested, and ultimately delivered to patients.
References
1. Exposure–Response Relationships: Study Design, Data Analysis, and Regulatory Applications: Guidance for Industry. U.S. Food and Drug Administration. May 2003.
2. Ruiz-Garcia, Ana, et al. “A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development.” J. Pharmacokinet. Pharmacodyn. 40: 147–172 (2023).
3. “Modelling and simulation: questions and answers.” European Medicines Agency. Accessed 12 Jan. 2026.
4. Wicha, SG. “From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics.” Clinical Pharmacology and Therapeutics. 4 Jan. 2021.
5. Tonge, Peter J. “Drug–Target Kinetics in Drug Discovery.” ACS Chem. Neurosci. 9: 29–39 (2017).
6. Lee, Kin Sing Stephen, et al. “Drug-Target Residence Time Affects in Vivo Target Occupancy through Multiple Pathways.” ACS Cent. Sci. 5: 1614–1624 (2019).
7. Landersdorfer, Cornelia B and Roger L Nation. “Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward.” Front. Pharmacol. Sec. Translational Pharmacology. 28 Oct. 2021.
8. Sinner, Patricia J and Linda Miller. “Understanding Pharmacokinetics (PK) and Pharmacodynamics (PD).” CLSI. 2018.
9. Clinical Pharmacology and Biopharmaceutics Review: 214256Orig1s000. Center for Drug Evaluation and Research. Accessed 12 Jan. 2026.
10. “FDA approves new dosing regimen for pembrolizumab.” U.S. Food and Drug Administration. 29 Apr. 2020.
11. Lala, Mallika, et al. “A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.” Eur. J. Cancer. 141: 68–75 (2020).
12. Overgaard, RV, SH Ingwersen, and CW Tornøe. “Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development.” CPT Pharmacometrics Syst,. Pharmacol. 4: 565–575 (2015).
13. Savitz, Adam J, et al. “Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.” Int. J. Neuropsychopharmacol. 19: pyw018 (2016).
14. NCT01515423: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia. ClinicalTrials.gov. 2 May 2016.
15. Najarian, Dean, et al. “A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.” Int. J. Neuropsychopharmacol. 25: 238–251 (2021).
16. Rizzardini, Giuliano, et al. “Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.” J. Acquir. Immune Defic. Syndr. 85: 498–506 (2020).
17. NCT02951052: Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults. ClinicalTrials.gov. 31 Dec. 2025. h
18. “Vivitrol (naltrexone for extended-release injectable suspension) Prescribing Information.” Accessed 12 Jan. 2026.
19. Comer, Sandra D, et al. “Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.” Arch Gen Psychiatry. 63: 210–218 (2006).
20. NCT02032433: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment. ClinicalTrials.gov. 13 Aug. 2020.
21. Endrenyi, Laszlo and Laszlo Tothfalusi. “Metrics for the Evaluation of Bioequivalence of Modified-Release Formulations.” AAPS J. 14: 813–819 (2012).
22. Drug Interaction Studies M12. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 21 May 2024.
